The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.
 
Hung-Yang Kuo
Stock and Other Ownership Interests - AstraZeneca; Exelixis/Ipsen
 
Jhe-Cyuan Guo
Stock and Other Ownership Interests - Exelixis/Ipsen
Honoraria - Merck; Ono Pharmaceutical
 
Ta-Chen Huang
No Relationships to Disclose
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Jang-Ming Lee
No Relationships to Disclose
 
Kun-Huei Yeh
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Ono Pharmaceutical; Takeda
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche/Genentech